Therapeutic angiogenesis is a new revascularization strategy involving the administration of growth factors to induce new vessel formation. The biology and delivery of angiogenic growth factors involved in vessel formation have been extensively studied but success in translating the angiogenic capacity of growth factors into benefits for vascular disease patients is still limited. This could be attributed to issues related to patient selection, growth factor delivery methods or lack of vessel maturation. Comprehensive understanding of the cellular and molecular cross-talk during the different stages of vascular development is needed for the design of efficient therapeutic strategies. The presentation of angiogenic factors either in series or in parallel using a strategy that mimics physiological events, such as concentration and spatio-temporal profiles, is an immediate requirement for functional blood vessel formation. This review provides an overview of the recent delivery strategies of angiogenic factors and discusses targeting neovascular maturation as a promising approach to induce stable and functional vessels for therapeutic angiogenesis.

1.
Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, Turner MB: Heart disease and stroke statistics – 2012 update: a report from the American Heart Association. Circulation 2012;125:e2–e220.
2.
Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A: Growing epidemic of coronary heart disease in low- and middle-income countries. Curr Probl Cardiol 2010;35:72–115.
3.
Zhang G, Suggs LJ: Matrices and scaffolds for drug delivery in vascular tissue engineering. Adv Drug Deliv Rev 2007;59:360–373.
4.
Williams B, Menon M, Satran D, Hayward D, Hodges JS, Burke MN, Johnson RK, Poulose AK, Traverse JH, Henry TD: Patients with coronary artery disease not amenable to traditional revascularization: prevalence and 3-year mortality. Catheter Cardiovasc Interv 2010;75:886–891.
5.
Mitsos S, Katsanos K, Koletsis E, Kagadis GC, Anastasiou N, Diamantopoulos A, Karnabatidis D, Dougenis D: Therapeutic angiogenesis for myocardial ischemia revisited: basic biological concepts and focus on latest clinical trials. Angiogenesis 2012;15:1–22.
6.
Losordo DW, Dimmeler S: Therapeutic angiogenesis and vasculogenesis for ischemic disease. Part I: angiogenic cytokines. Circulation 2004;109:2487–2491.
7.
Losordo DW, Dimmeler S: Therapeutic angiogenesis and vasculogenesis for ischemic disease. Part II: cell-based therapies. Circulation 2004;109:2692–2697.
8.
Gupta R, Tongers J, Losordo DW: Human studies of angiogenic gene therapy. Circ Res 2009;105:724–736.
9.
Lekas M, Lekas P, Latter DA, Kutryk MB, Stewart DJ: Growth factor-induced therapeutic neovascularization for ischaemic vascular disease: time for a re-evaluation? Curr Opin Cardiol 2006;21:376–384.
10.
Robich MP, Chu LM, Oyamada S, Sodha NR, Sellke FW: Myocardial therapeutic angiogenesis: a review of the state of development and future obstacles. Expert Rev Cardiovasc Ther 2011;9:1469–1479.
11.
Conway EM, Collen D, Carmeliet P: Molecular mechanisms of blood vessel growth. Cardiovasc Res 2001;49:507–521.
12.
Luttun A, Carmeliet P: De novo vasculogenesis in the heart. Cardiovasc Res 2003;58:378–389.
13.
Adair TH, Montani JP: Angiogenesis; in Granger DN, Granger JP (eds): Integrated Systems Physiology: from Molecule to Function to Disease. New Jersey, Morgan & Claypool Life Sciences, 2010, pp 1–84.
14.
Li B, Sharpe EE, Maupin AB, Teleron AA, Pyle AL, Carmeliet P, Young PP: VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J 2006;20:1495–1497.
15.
Schaper W: Collateral circulation: past and present. Basic Res Cardiol 2009;104:5–21.
16.
Ferrara N, Kerbel RS: Angiogenesis as a therapeutic target. Nature 2005;438:967–974.
17.
Cao L, Mooney DJ: Spatiotemporal control over growth factor signaling for therapeutic neovascularization. Adv Drug Deliv Rev 2007;59:1340–1350.
18.
The Angiogenesis Foundation: Understanding angiogenesis: the angiogenesis process. http://www.angio.org/understanding/process.php (accessed July 29, 2012).
19.
Davis GE, Stratman AN, Sacharidou A, Koh W: Molecular basis for endothelial lumen formation and tubulogenesis during vasculogenesis and angiogenic sprouting. Int Rev Cell Mol Biol 2011;288:101–165.
20.
Stratman AN, Davis GE: Endothelial cell-pericyte interactions stimulate basement membrane matrix assembly: influence on vascular tube remodeling, maturation, and stabilization. Microsc Microanal 2012;18:68–80.
21.
Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604–4613.
22.
Tammela T, Enholm B, Alitalo K, Paavonen K: The biology of vascular endothelial growth factors. Cardiovasc Res 2005;65:550–563.
23.
Roy H, Bhardwaj S, Yla-Herttuala S: Biology of vascular endothelial growth factors. FEBS Lett 2006;580:2879–2887.
24.
Yla-Herttuala S, Rissanen TT, Vajanto I, Hartikainen J: Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 2007;49:1015–1026.
25.
Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L: VEGF receptor signalling – in control of vascular function. Nat Rev Mol Cell Biol 2006;7:359–371.
26.
Bruce D, Tan PH: Vascular endothelial growth factor receptors and the therapeutic targeting of angiogenesis in cancer: where do we go from here? Cell Commun Adhes 2011;18:85–103.
27.
Shibuya M: Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 2006;39:469–478.
28.
Tabibiazar R, Rockson SG: Angiogenesis and the ischaemic heart. Eur Heart J 2001;22:903–918.
29.
Unemori EN, Ferrara N, Bauer EA, Amento EP: Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 1992;153:557–562.
30.
Costa C, Soares R, Reis-Filho JS, Leitao D, Amendoeira I, Schmitt FC: Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 2002;55:429–434.
31.
Li J, Brown LF, Hibberd MG, Grossman JD, Morgan JP, Simons M: VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol 1996;270:H1803–H1811.
32.
Kalka C, Masuda H, Takahashi T, Gordon R, Tepper O, Gravereaux E, Pieczek A, Iwaguro H, Hayashi SI, Isner JM, Asahara T: Vascular endothelial growth factor165 gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res 2000;86:1198–1202.
33.
Presta M, Dell’Era P, Mitola S, Moroni E, Ronca R, Rusnati M: Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005;16:159–178.
34.
Itoh N, Ornitz DM: Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem 2011;149:121–130.
35.
Venkataraman G, Raman R, Sasisekharan V, Sasisekharan R: Molecular characteristics of fibroblast growth factor-fibroblast growth factor receptor-heparin-like glycosaminoglycan complex. Proc Natl Acad Sci USA 1999;96:3658–3663.
36.
Distler JH, Hirth A, Kurowska-Stolarska M, Gay RE, Gay S, Distler O: Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med 2003;47:149–161.
37.
Cao R, Brakenhielm E, Pawliuk R, Wariaro D, Post MJ, Wahlberg E, Leboulch P, Cao Y: Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 2003;9:604–613.
38.
Wang XT, Liu PY, Tang JB: PDGF gene therapy enhances expression of VEGF and bFGF genes and activates the NF-kappaB gene in signal pathways in ischemic flaps. Plast Reconstr Surg 2006;117:129–139.
39.
Alvarez RH, Kantarjian HM, Cortes JE: Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc 2006;81:1241–1257.
40.
Chang SH, Hla T: Gene regulation by RNA binding proteins and microRNAs in angiogenesis. Trends Mol Med 2011;17:650– 658.
41.
Bernstein E, Kim SY, Carmell MA, Murchison EP, Alcorn H, Li MZ, Mills AA, Elledge SJ, Anderson KV, Hannon GJ: Dicer is essential for mouse development. Nat Genet 2003;35:215–217.
42.
Yang WJ, Yang DD, Na S, Sandusky GE, Zhang Q, Zhao G: Dicer is required for embryonic angiogenesis during mouse development. J Biol Chem 2005;280:9330–9335.
43.
Kuehbacher A, Urbich C, Zeiher AM, Dimmeler S: Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Circ Res 2007;101:59–68.
44.
Suarez Y, Fernandez-Hernando C, Yu J, Gerber SA, Harrison KD, Pober JS, Iruela-Arispe ML, Merkenschlager M, Sessa WC: Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis. Proc Natl Acad Sci USA 2008;105:14082–14087.
45.
Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, Richardson JA, Bassel-Duby R, Olson EN: The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008;15:261–271.
46.
Garzon R, Pichiorri F, Palumbo T, Iuliano R, Cimmino A, Aqeilan R, Volinia S, Bhatt D, Alder H, Marcucci G, Calin GA, Liu CG, Bloomfield CD, Andreeff M, Croce CM: MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci USA 2006;103:5078–5083.
47.
van Rooij E, Marshall WS, Olson EN: Toward microRNA-based therapeutics for heart disease: the sense in antisense. Circ Res 2008;103:919–928.
48.
Suarez Y, Sessa WC: MicroRNAs as novel regulators of angiogenesis. Circ Res 2009;104:442–454.
49.
Ruel M, Sellke FW: Angiogenic protein therapy. Semin Thorac Cardiovasc Surg 2003;15:222–235.
50.
Sellke FW, Ruel M: Vascular growth factors and angiogenesis in cardiac surgery. Ann Thorac Surg 2003;75:S685–S690.
51.
Tsurumi Y, Takeshita S, Chen D, Kearney M, Rossow ST, Passeri J, Horowitz JR, Symes JF, Isner JM: Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 1996;94:3281–3290.
52.
Vale PR, Losordo DW, Milliken CE, McDonald MC, Gravelin LM, Curry CM, Esakof DD, Maysky M, Symes JF, Isner JM: Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation 2001;103:2138–2143.
53.
Hedman M, Hartikainen J, Syvanne M, Stjernvall J, Hedman A, Kivela A, Vanninen E, Mussalo H, Kauppila E, Simula S, Narvanen O, Rantala A, Peuhkurinen K, Nieminen MS, Laakso M, Yla-Herttuala S: Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003;107:2677–2683.
54.
Kastrup J, Jorgensen E, Ruck A, Tagil K, Glogar D, Ruzyllo W, Botker HE, Dudek D, Drvota V, Hesse B, Thuesen L, Blomberg P, Gyongyosi M, Sylven C: Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial. J Am Coll Cardiol 2005;45:982–988.
55.
McMahon JM, Wells KE, Bamfo JE, Cartwright MA, Wells DJ: Inflammatory responses following direct injection of plasmid DNA into skeletal muscle. Gene Ther 1998;5:1283–1290.
56.
Wright MJ, Wightman LM, Lilley C, de Alwis M, Hart SL, Miller A, Coffin RS, Thrasher A, Latchman DS, Marber MS: In vivo myocardial gene transfer: optimization, evaluation and direct comparison of gene transfer vectors. Basic Res Cardiol 2001;96:227–236.
57.
Laitinen M, Pakkanen T, Donetti E, Baetta R, Luoma J, Lehtolainen P, Viita H, Agrawal R, Miyanohara A, Friedmann T, Risau W, Martin JF, Soma M, Yla-Herttuala S: Gene transfer into the carotid artery using an adventitial collar: comparison of the effectiveness of the plasmid-liposome complexes, retroviruses, pseudotyped retroviruses, and adenoviruses. Hum Gene Ther 1997;8:1645–1650.
58.
Kankkonen HM, Vahakangas E, Marr RA, Pakkanen T, Laurema A, Leppanen P, Jalkanen J, Verma IM, Yla-Herttuala S: Long-term lowering of plasma cholesterol levels in LDL-receptor-deficient WHHL rabbits by gene therapy. Mol Ther 2004;9:548–556.
59.
Masaki I, Yonemitsu Y, Komori K, Ueno H, Nakashima Y, Nakagawa K, Fukumura M, Kato A, Hasan MK, Nagai Y, Sugimachi K, Hasegawa M, Sueishi K: Recombinant Sendai virus-mediated gene transfer to vasculature: a new class of efficient gene transfer vector to the vascular system. Faseb J 2001;15:1294–1296.
60.
Coffin RS, Howard MK, Cumming DV, Dollery CM, McEwan J, Yellon DM, Marber MS, MacLean AR, Brown SM, Latchman DS: Gene delivery to the heart in vivo and to cardiac myocytes and vascular smooth muscle cells in vitro using herpes virus vectors. Gene Ther 1996;3:560–566.
61.
Airenne KJ, Hiltunen MO, Turunen MP, Turunen AM, Laitinen OH, Kulomaa MS, Yla-Herttuala S: Baculovirus-mediated periadventitial gene transfer to rabbit carotid artery. Gene Ther 2000;7:1499–1504.
62.
Rissanen TT, Yla-Herttuala S: Current status of cardiovascular gene therapy. Mol Ther 2007;15:1233–1247.
63.
Gruchala M, Bhardwaj S, Pajusola K, Roy H, Rissanen TT, Kokina I, Kholova I, Markkanen JE, Rutanen J, Heikura T, Alitalo K, Bueler H, Yla-Herttuala S: Gene transfer into rabbit arteries with adeno-associated virus and adenovirus vectors. J Gene Med 2004;6:545–554.
64.
Su H, Huang Y, Takagawa J, Barcena A, Arakawa-Hoyt J, Ye J, Grossman W, Kan YW: AAV serotype-1 mediates early onset of gene expression in mouse hearts and results in better therapeutic effect. Gene Ther 2006;13:1495–1502.
65.
Formiga FR, Pelacho B, Garbayo E, Abizanda G, Gavira JJ, Simon-Yarza T, Mazo M, Tamayo E, Jauquicoa C, Ortiz-de-Solorzano C, Prosper F, Blanco-Prieto MJ: Sustained release of VEGF through PLGA microparticles improves vasculogenesis and tissue remodeling in an acute myocardial ischemia-reperfusion model. J Control Release 2010;147:30–37.
66.
Gao J, Liu J, Gao Y, Wang C, Zhao Y, Chen B, Xiao Z, Miao Q, Dai J: A myocardial patch made of collagen membranes loaded with collagen-binding human vascular endothelial growth factor accelerates healing of the injured rabbit heart. Tissue Eng Part A 2011;17:2739–2747.
67.
Miyagi Y, Chiu LL, Cimini M, Weisel RD, Radisic M, Li RK: Biodegradable collagen patch with covalently immobilized VEGF for myocardial repair. Biomaterials 2011;32:1280–1290.
68.
Cittadini A, Monti MG, Petrillo V, Esposito G, Imparato G, Luciani A, Urciuolo F, Bobbio E, Natale CF, Sacca L, Netti PA: Complementary therapeutic effects of dual delivery of insulin-like growth factor-1 and vascular endothelial growth factor by gelatin microspheres in experimental heart failure. Eur J Heart Fail 2011;13:1264–1274.
69.
Rutanen J, Rissanen TT, Markkanen JE, Gruchala M, Silvennoinen P, Kivela A, Hedman A, Hedman M, Heikura T, Orden MR, Stacker SA, Achen MG, Hartikainen J, Yla-Herttuala S: Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart. Circulation 2004;109:1029–1035.
70.
Schaper W, Ito WD: Molecular mechanisms of coronary collateral vessel growth. Circ Res 1996;79:911–919.
71.
Unger EF, Banai S, Shou M, Jaklitsch M, Hodge E, Correa R, Jaye M, Epstein SE: A model to assess interventions to improve collateral blood flow: continuous administration of agents into the left coronary artery in dogs. Cardiovasc Res 1993;27:785–791.
72.
Iwakura A, Fujita M, Kataoka K, Tambara K, Sakakibara Y, Komeda M, Tabata Y: Intramyocardial sustained delivery of basic fibroblast growth factor improves angiogenesis and ventricular function in a rat infarct model. Heart Vessels 2003;18:93–99.
73.
Nie SP, Wang X, Qiao SB, Zeng QT, Jiang JQ, Liu XQ, Zhu XM, Cao GX, Ma CS: Improved myocardial perfusion and cardiac function by controlled-release basic fibroblast growth factor using fibrin glue in a canine infarct model. J Zhejiang Univ Sci B 2010;11:895–904.
74.
Sakakibara Y, Tambara K, Sakaguchi G, Lu F, Yamamoto M, Nishimura K, Tabata Y, Komeda M: Toward surgical angiogenesis using slow-released basic fibroblast growth factor. Eur J Cardiothorac Surg 2003;24:105– 112.
75.
Grines C, Rubanyi GM, Kleiman NS, Marrott P, Watkins MW: Angiogenic gene therapy with adenovirus 5 fibroblast growth factor-4 (Ad5FGF-4): a new option for the treatment of coronary artery disease. Am J Cardiol 2003;92:24N–31N.
76.
von Tell D, Armulik A, Betsholtz C: Pericytes and vascular stability. Exp Cell Res 2006;312:623–629.
77.
Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E: Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;103:159–165.
78.
Stratman AN, Davis GE: Endothelial cell-pericyte interactions stimulate basement membrane matrix assembly: influence on vascular tube remodeling, maturation, and stabilization. Microsc Microanal 2012;18:68–80.
79.
Senger DR, Davis GE: Angiogenesis. Cold Spring Harb Perspect Biol 2011;3:a005090.
80.
Steed DL: Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers. Plast Reconstr Surg 2006;117:143S–151S.
81.
Niklason LE: Building stronger microvessels. Nat Biotechnol 2011;29:405–406.
82.
Valentijn KM, Sadler JE, Valentijn JA, Voorberg J, Eikenboom J: Functional architecture of Weibel-Palade bodies. Blood 2011;117:5033–5043.
83.
Starke RD, Ferraro F, Paschalaki KE, Dryden NH, McKinnon TA, Sutton RE, Payne EM, Haskard DO, Hughes AD, Cutler DF, Laffan MA, Randi AM: Endothelial von Willebrand factor regulates angiogenesis. Blood 2011;117:1071–1080.
84.
Scheppke L, Murphy EA, Zarpellon A, Hofmann JJ, Merkulova A, Shields DJ, Weis SM, Byzova TV, Ruggeri ZM, Iruela-Arispe ML, Cheresh DA: Notch promotes vascular maturation by inducing integrin-mediated smooth muscle cell adhesion to the endothelial basement membrane. Blood 2012;119:2149–2158.
85.
Stewart DJ, Kutryk MJ, Fitchett D, Freeman M, Camack N, Su Y, Della Siega A, Bilodeau L, Burton JR, Proulx G, Radhakrishnan S: VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. Mol Ther 2009;17:1109–1115.
86.
Greenberg JI, Shields DJ, Barillas SG, Acevedo LM, Murphy E, Huang J, Scheppke L, Stockmann C, Johnson RS, Angle N, Cheresh DA: A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 2008;456:809–813.
87.
Murakami M, Simons M: Regulation of vascular integrity. J Mol Med (Berl) 2009;87:571–582.
88.
Tsigkou O, Pomerantseva I, Spencer JA, Redondo PA, Hart AR, O’Doherty E, Lin Y, Friedrich CC, Daheron L, Lin CP, Sundback CA, Vacanti JP, Neville C: Engineered vascularized bone grafts. Proc Natl Acad Sci USA 2010;107:3311–3316.
89.
Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, Glazer N, Holash J, McDonald DM, Yancopoulos GD: Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000;6:460–463.
90.
Jiang J, Jiangl N, Gao W, Zhu J, Guo Y, Shen D, Chen G, Tang J: Augmentation of revascularization and prevention of plasma leakage by angiopoietin-1 and vascular endothelial growth factor co-transfection in rats with experimental limb ischaemia. Acta Cardiol 2006;61:145–153.
91.
Smith AH, Kuliszewski MA, Liao C, Rudenko D, Stewart DJ, Leong-Poi H: Sustained improvement in perfusion and flow reserve after temporally separated delivery of vascular endothelial growth factor and angiopoietin-1 plasmid deoxyribonucleic acid. J Am Coll Cardiol 2012;59:1320–1328.
92.
Zhou YF, Stabile E, Walker J, Shou M, Baffour R, Yu Z, Rott D, Yancopoulos GD, Rudge JS, Epstein SE: Effects of gene delivery on collateral development in chronic hypoperfusion: diverse effects of angiopoietin-1 versus vascular endothelial growth factor. J Am Coll Cardiol 2004;44:897–903.
93.
Tao Z, Chen B, Tan X, Zhao Y, Wang L, Zhu T, Cao K, Yang Z, Kan YW, Su H: Coexpression of VEGF and angiopoietin-1 promotes angiogenesis and cardiomyocyte proliferation reduces apoptosis in porcine myocardial infarction (MI) heart. Proc Natl Acad Sci USA 2011;108:2064–2069.
94.
Richardson TP, Peters MC, Ennett AB, Mooney DJ: Polymeric system for dual growth factor delivery. Nat Biotechnol 2001;19:1029–1034.
95.
Kupatt C, Hinkel R, Pfosser A, El-Aouni C, Wuchrer A, Fritz A, Globisch F, Thormann M, Horstkotte J, Lebherz C, Thein E, Banfi A, Boekstegers P: Cotransfection of vascular endothelial growth factor-A and platelet-derived growth factor-B via recombinant adeno-associated virus resolves chronic ischemic malperfusion role of vessel maturation. J Am Coll Cardiol 2010;56:414–422.
96.
Levitzki A: PDGF receptor kinase inhibitors for the treatment of restenosis. Cardiovasc Res 2005;65:581–586.
97.
Banquet S, Gomez E, Nicol L, Edwards-Levy F, Henry JP, Cao R, Schapman D, Dautreaux B, Lallemand F, Bauer F, Cao Y, Thuillez C, Mulder P, Richard V, Brakenhielm E: Arteriogenic therapy by intramyocardial sustained delivery of a novel growth factor combination prevents chronic heart failure. Circulation 2011;124:1059–1069.
98.
Frontini MJ, Nong Z, Gros R, Drangova M, O’Neil C, Rahman MN, Akawi O, Yin H, Ellis CG, Pickering JG: Fibroblast growth factor 9 delivery during angiogenesis produces durable, vasoresponsive microvessels wrapped by smooth muscle cells. Nat Biotechnol 2011;29:421–427.
99.
Renault MA, Losordo DW: Therapeutic myocardial angiogenesis. Microvasc Res 2007;74:159–171.
100.
Lee KY, Peters MC, Mooney DJ: Comparison of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in SCID mice. J Control Release 2003;87:49–56.
101.
Freedman SB, Isner JM: Therapeutic angiogenesis for coronary artery disease. Ann Intern Med 2002;136:54–71.
102.
Simons M, Ware JA: Therapeutic angiogenesis in cardiovascular disease. Nat Rev Drug Discov 2003;2:863–871.
103.
King TW, Patrick CW Jr: Development and in vitro characterization of vascular endothelial growth factor (VEGF)-loaded poly(DL- lactic-co-glycolic acid)/poly(ethylene glycol) microspheres using a solid encapsulation/single emulsion/solvent extraction technique. J Biomed Mater Res 2000;51:383–390.
104.
Zisch AH, Lutolf MP, Hubbell JA: Biopolymeric delivery matrices for angiogenic growth factors. Cardiovasc Pathol 2003;12:295–310.
105.
Patel ZS, Mikos AG: Angiogenesis with biomaterial-based drug- and cell-delivery systems. J Biomater Sci Polym Ed 2004;15:701–726.
106.
Brey EM, Uriel S, Greisler HP, McIntire LV: Therapeutic neovascularization: contributions from bioengineering. Tissue Eng 2005;11:567–584.
107.
Murphy WL, Peters MC, Kohn DH, Mooney DJ: Sustained release of vascular endothelial growth factor from mineralized poly(lactide-co-glycolide) scaffolds for tissue engineering. Biomaterials 2000;21:2521–2527.
108.
Cleland JL, Duenas ET, Park A, Daugherty A, Kahn J, Kowalski J, Cuthbertson A: Development of poly-(D,L-lactide–coglycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis. J Control Release 2001;72:13–24.
109.
Briganti E, Spiller D, Mirtelli C, Kull S, Counoupas C, Losi P, Senesi S, Di Stefano R, Soldani G: A composite fibrin-based scaffold for controlled delivery of bioactive pro-angiogenetic growth factors. J Control Release 2010;142:14–21.
110.
Steffens GC, Yao C, Prevel P, Markowicz M, Schenck P, Noah EM, Pallua N: Modulation of angiogenic potential of collagen matrices by covalent incorporation of heparin and loading with vascular endothelial growth factor. Tissue Eng 2004;10:1502–1509.
111.
Silva EA, Mooney DJ: Spatiotemporal control of vascular endothelial growth factor delivery from injectable hydrogels enhances angiogenesis. J Thromb Haemost 2007;5:590–598.
112.
Ishihara M, Obara K, Nakamura S, Fujita M, Masuoka K, Kanatani Y, Takase B, Hattori H, Morimoto Y, Ishihara M, Maehara T, Kikuchi M: Chitosan hydrogel as a drug delivery carrier to control angiogenesis. J Artif Organs 2006;9:8–16.
113.
Young S, Wong M, Tabata Y, Mikos AG: Gelatin as a delivery vehicle for the controlled release of bioactive molecules. J Control Release 2005;109:256–274.
114.
Lee KY, Mooney DJ: Hydrogels for tissue engineering. Chem Rev 2001;101:1869–1879.
115.
Chen RR, Mooney DJ: Polymeric growth factor delivery strategies for tissue engineering. Pharm Res 2003;20:1103–1112.
116.
Mooney DJ, Baldwin DF, Suh NP, Vacanti JP, Langer R: Novel approach to fabricate porous sponges of poly(d,l-lactic-co-glycolic acid) without the use of organic solvents. Biomaterials 1996;17:1417–1422.
117.
Liao IC, Leong KW: Efficacy of engineered FVIII-producing skeletal muscle enhanced by growth factor-releasing co-axial electrospun fibers. Biomaterials 2010;32:1669–1677.
118.
Sahoo S, Ang LT, Goh JC, Toh SL: Growth factor delivery through electrospun nanofibers in scaffolds for tissue engineering applications. J Biomed Mater Res 2010;93A:1539–1550.
119.
Zou J, Yang Y, Liu Y, Chen F, Li X: Release kinetics and cellular profiles for bFGF-loaded electrospun fibers: effect of the conjugation density and molecular weight of heparin. Polymer 2011;52:3357–3367.
120.
Sakiyama-Elbert SE, Hubbell JA: Development of fibrin derivatives for controlled release of heparin-binding growth factors. J Control Release 2000;65:389–402.
121.
Wong C, Inman E, Spaethe R, Helgerson S: Fibrin-based biomaterials to deliver human growth factors. Thromb Haemost 2003;89:573–582.
122.
Sahni A, Francis CW: Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood 2000;96:3772–3778.
123.
Giannoni P, Hunziker EB: Release kinetics of transforming growth factor-β1 from fibrin clots. Biotechnol Bioeng 2003;83:121–123.
124.
Jeon O, Ryu SH, Chung JH, Kim BS: Control of basic fibroblast growth factor release from fibrin gel with heparin and concentrations of fibrinogen and thrombin. J Control Release 2005;105:249–259.
125.
Masuda S, Doi K, Satoh S, Oka T, Matsuda T: Vascular endothelial growth factor enhances vascularization in microporous small caliber polyurethane grafts. ASAIO J 1997;43:M530–M534.
126.
Swanson N, Hogrefe K, Javed Q, Gershlick AH: In vitro evaluation of vascular endothelial growth factor (VEGF)-eluting stents. Int J Cardiol 2003;92:247–251.
127.
Li JS, Ito Y, Zheng J, Takahashi T, Imanishi Y: Enhancement of artificial juxtacrine stimulation of insulin by co-immobilization with adhesion factors. J Biomed Mater Res 1997;37:190–197.
128.
DeLong SA, Moon JJ, West JL: Covalently immobilized gradients of bFGF on hydrogel scaffolds for directed cell migration. Biomaterials 2005;26:3227–3234.
129.
Li L, Chu CC: Nitroxyl radical incorporated electrospun biodegradable poly(ester Amide) nanofiber membranes. J Biomater Sci Polym Ed 2009;20:341–361.
130.
Casper CL, Yamaguchi N, Kiick KL, Rabolt JF: Functionalizing electrospun fibers with biologically relevant macromolecules. Biomacromolecules 2005;6:1998–2007.
131.
Mottaghitalaba F, Farokhia M, Mottaghitalabd V, Mohammad Ziabarie, Divsalarf A, Shokrgozara MA: Enhancement of neural cell lines proliferation using nano-structured chitosan/poly(vinyl alcohol) scaffolds conjugated with nerve growth factor. Carbohydr Polym 2011;86:526–535.
132.
Yang Y, Xia T, Zhi W, Wei L, Weng J, Zhang C, Li X: Promotion of skin regeneration in diabetic rats by electrospun core-sheath fibers loaded with basic fibroblast growth factor. Biomaterials 2011;32:4243–4254.
133.
Montero RB, Vial X, Nguyen DT, Farhand S, Reardon M, Pham SM, Tsechpenakis G, Andreopoulos FM: bFGF-containing electrospun gelatin scaffolds with controlled nano-architectural features for directed angiogenesis. Acta Biomater 2012;8:1778–1791.
134.
Bezuidenhout D, Davies N, Zilla P: Effect of well defined dodecahedral porosity on inflammation and angiogenesis. Asaio J 2002;48:465–471.
135.
Ennett AB, Kaigler D, Mooney DJ: Temporally regulated delivery of VEGF in vitro and in vivo. J Biomed Mater Res A 2006;79:176–184.
136.
Seliktar D, Zisch AH, Lutolf MP, Wrana JL, Hubbell JA: MMP-2 sensitive, VEGF-bearing bioactive hydrogels for promotion of vascular healing. J Biomed Mater Res A 2004;68:704–716.
137.
Zisch AH, Lutolf MP, Ehrbar M, Raeber GP, Rizzi SC, Davies N, Schmokel H, Bezuidenhout D, Djonov V, Zilla P, Hubbell JA: Cell-demanded release of VEGF from synthetic, biointeractive cell ingrowth matrices for vascularized tissue growth. Faseb J 2003;17:2260–2262.
138.
Lee KY, Peters MC, Anderson KW, Mooney DJ: Controlled growth factor release from synthetic extracellular matrices. Nature 2000;408:998–1000.
139.
Peirce SM, Price RJ, Skalak TC: Spatial and temporal control of angiogenesis and arterialization using focal applications of VEGF164 and Ang-1. Am J Physiol Heart Circ Physiol 2004;286:H918–H925.
140.
Chen RR, Silva EA, Yuen WW, Mooney DJ: Spatio-temporal VEGF and PDGF delivery patterns blood vessel formation and maturation. Pharm Res 2007;24:258–264.
141.
Massia SP, Hubbell JA: Human endothelial cell interactions with surface-coupled adhesion peptides on a nonadhesive glass substrate and two polymeric biomaterials. J Biomed Mater Res 1991;25:223–242.
142.
Kong HJ, Boontheekul T, Mooney DJ: Quantifying the relation between adhesion ligand-receptor bond formation and cell phenotype. Proc Natl Acad Sci USA 2006;103:18534–18539.
143.
Tsang VL, Bhatia SN: Three-dimensional tissue fabrication. Adv Drug Deliv Rev 2004;56:1635–1647.
144.
Staples M, Daniel K, Cima MJ, Langer R: Application of micro- and nano-electromechanical devices to drug delivery. Pharm Res 2006;23:847–863.
145.
LaVan DA, McGuire T, Langer R: Small-scale systems for in vivo drug delivery. Nat Biotechnol 2003;21:1184–1191.
146.
Farokhzad OC, Langer R: Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev 2006;58:1456–1459.
147.
Mitsos S, Katsanos K, Koletsis E, Kagadis GC, Anastasiou N, Diamantopoulos A, Karnabatidis D, Dougenis D: Therapeutic angiogenesis for myocardial ischemia revisited: basic biological concepts and focus on latest clinical trials. Angiogenesis 2012;15:1–22.
148.
Lopez JJ, Laham RJ, Carrozza JP, Tofukuji M, Sellke FW, Bunting S, Simons M: Hemodynamic effects of intracoronary VEGF delivery: evidence of tachyphylaxis and NO dependence of response. Am J Physiol 1997;273:H1317–H1323.
149.
Cuevas P, Garcia-Calvo M, Carceller F, Reimers D, Zazo M, Cuevas B, Munoz-Willery I, Martinez-Coso V, Lamas S, Gimenez-Gallego G: Correction of hypertension by normalization of endothelial levels of fibroblast growth factor and nitric oxide synthase in spontaneously hypertensive rats. Proc Natl Acad Sci USA 1996;93:11996–12001.
150.
Horowitz JR, Rivard A, van der Zee R, Hariawala M, Sheriff DD, Esakof DD, Chaudhry GM, Symes JF, Isner JM: Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension: evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vasc Biol 1997;17:2793–2800.
151.
Sasaki T, Jyo Y, Tanda N, Kawakami Y, Nohno T, Tamai H, Osawa G: Changes in glomerular epithelial cells induced by FGF2 and FGF2 neutralizing antibody in puromycin aminonucleoside nephropathy. Kidney Int 1997;51:301–309.
152.
Unger EF, Goncalves L, Epstein SE, Chew EY, Trapnell CB, Cannon RO 3rd, Quyyumi AA: Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris. Am J Cardiol 2000;85:1414–1419.
153.
Mazue G, Bertolero F, Jacob C, Sarmientos P, Roncucci R: Preclinical and clinical studies with recombinant human basic fibroblast growth factor. Ann NY Acad Sci 1991;638:329–340.
154.
Baumgartner I, Rauh G, Pieczek A, Wuensch D, Magner M, Kearney M, Schainfeld R, Isner JM: Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor. Ann Intern Med 2000;132:880–884.
155.
Carmeliet P: VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nat Med 2000;6:1102–1103.
156.
Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC, Blau HM: VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 2000;102:898–901.
157.
Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27–31.
158.
Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, Shah PK, Willerson JT, Benza RL, Berman DS, Gibson CM, Bajamonde A, Rundle AC, Fine J, McCluskey ER: The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003;107:1359–1365.
159.
Schumacher B, Pecher P, von Specht BU, Stegmann T: Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 1998;97:645–650.
160.
Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, Ashare AB, Lathi K, Isner JM: Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998;98:2800–2804.
161.
Seiler C, Pohl T, Wustmann K, Hutter D, Nicolet PA, Windecker S, Eberli FR, Meier B: Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. Circulation 2001;104:2012–2017.
162.
Zbinden S, Zbinden R, Meier P, Windecker S, Seiler C: Safety and efficacy of subcutaneous-only granulocyte-macrophage colony-stimulating factor for collateral growth promotion in patients with coronary artery disease. J Am Coll Cardiol 2005;46:1636–1642.
163.
Zohlnhofer D, Ott I, Mehilli J, Schomig K, Michalk F, Ibrahim T, Meisetschlager G, von Wedel J, Bollwein H, Seyfarth M, Dirschinger J, Schmitt C, Schwaiger M, Kastrati A, Schomig A: Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. JAMA 2006;295:1003–1010.
164.
Ripa RS, Jorgensen E, Wang Y, Thune JJ, Nilsson JC, Sondergaard L, Johnsen HE, Kober L, Grande P, Kastrup J: Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: result of the double-blind, randomized, placebo-controlled stem cells in myocardial infarction (STEMMI) trial. Circulation 2006;113:1983–1992.
165.
Laham RJ, Sellke FW, Edelman ER, Pearlman JD, Ware JA, Brown DL, Gold JP, Simons M: Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 1999;100:1865–1871.
166.
Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H, Udelson JE, Gervino EV, Pike M, Whitehouse MJ, Moon T, Chronos NA: Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002;105:788–793.
167.
Grines CL, Watkins MW, Helmer G, Penny W, Brinker J, Marmur JD, West A, Rade JJ, Marrott P, Hammond HK, Engler RL: Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002;105:1291–1297.
168.
Stewart DJ, Hilton JD, Arnold JM, Gregoire J, Rivard A, Archer SL, Charbonneau F, Cohen E, Curtis M, Buller CE, Mendelsohn FO, Dib N, Page P, Ducas J, Plante S, Sullivan J, Macko J, Rasmussen C, Kessler PD, Rasmussen HS: Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF121 (AdVEGF121) versus maximum medical treatment. Gene Ther 2006;13:1503–1511.
169.
Kastrup J, Jorgensen E, Fuchs S, Nikol S, Botker HE, Gyongyosi M, Glogar D, Kornowski R: A randomised, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: the NOVA trial. EuroIntervention 2011;6:813–818.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.